What the Study Found (In Plain English)
Published in Life sciences (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: Platelet mitochondrial bioenergetics contribute to vascular thrombosis in patients with end-stage renal disease (ESRD). Key clinical takeaway: The preHD-ET for 36 weeks improves systemic aerobic capacity in ESRD patients. Moreover, this exercise regimen enhances mitochondrial bioenergetics efficiency in platelets, whose responses are associated with increased VO 2peak in ESRD patients. Clinical trials registration No. NCT06417307.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Life sciences, 2026-07-01; Phase III Randomized Trial; Rigor 82/100): The preHD-ET for 36 weeks improves systemic aerobic capacity in ESRD patients. Moreover, this exercise regimen enhances mitochondrial bioenergetics efficiency in platelets, whose responses are associated with increased VO 2peak in ESRD patients. Clinical trials registration No. NCT06417307.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.